BriaCell Therapeutics Corp. (Nasdaq: BCTX) (TSX: BCT) CEO William Williams, MD – RICH TV LIVE – June 14, 2022 – #briacelltherapeutics #cancer #richtvlive #stocks #business #news #finance #education #interview #richtv #money #investing #trading #nasdaq
Hi how’s everybody doing today i’m your host rich on behalf of rich tv live with our very special guest dr bill williams the ceo of bria cell therapeutics corp how you doing today bill doing great rich it’s great to see you excited to have you back on the show now dr williams obviously it’s fantastic to have you back on the show the other day you guys announced
That you have added additional clinical sites can you go through this news for us and what it means for the company so i think the first thing to appreciate is that we’re operating now under fast track designation by the fda which means that they will they’ve recognized that our therapy may be safer and or more effective or both which we happen to think it’s
Both than what’s currently out there and that we’re treating an area of really large on medical need so it’s really imperative for us to get our therapy out to as many patients as we can even before we get our bria imt cellular immunotherapy for breast cancer approved for marketing authorization so these additional clinical sites will have several effects
First of all it will make our therapy more widely available which is great we’ve added hogue memorial which is in orange county in california and we’ve added the sylvester comprehensive cancer centers of the university miami uh in florida and so this will allow more patients access to our therapy but in addition it’ll speed enrollment in our clinical trials
Which are really uh critical in uh determining and showing the uh efficacy and the safety of our bria imt therapy so that we can eventually get marketing approval and get it out there to the widest number of patients possible bill with the additional clinical sites added how does that help with the overall valuation since briocell is pre-revenue yeah so biotech
Companies like briocell are developing novel therapies which have tremendous potential obviously for the patients primarily but also in terms of revenue generation down the line and our typical valuations come about by looking at the value of our assets and what they eventually are going to look like once they’re on the market and that’s an analysis that
We’ve had done by experts and i think that uh we are markedly undervalued right now but the thing that’s really key with the clinical sites is that as they enroll patients in the clinical study that we have ongoing we’ll be able to move forward through the regulatory process and get that much closer to the point where we’re doing a pivotal registration study
Now that’s a really key point in the life of any biotech company because once you have that pivotal registration study ongoing you know how long the study will take how much it will cost how many patients you need to enroll and all the fda regulatory hurdles will be clearly mapped out for you and that’s when big pharma companies come in and do really large
Multi-billion dollar licensing deals with small farmers like us these additional clinical sites will allow us to achieve those milestones out much more quickly to get to that pivotal registration study start so we’re really really excited about moving forward with these additional sites i’m excited to see this evolve and with the current market conditions
Investors are looking for fundamental growth and wanting to look for solid revenue growth with briocell being a pre-revenue biotech company what is the most important thing an investor should be looking for in a pre-revenue biotech company i think that there’s a few things that are really important for a biotech company in its valuation the first thing is
The technology is this technology something that looks like it’s going to work well we already have very positive clinical data in patients who have really failed every other attempt at therapy we had one lady who came to us with 20 different lung metastases so her breast cancer had traveled into her lungs and there are actually 20 breast cancer nodules in
Her lungs and we’re able to completely resolve or shrink down all 20 of those with a stable disease elsewhere but even more impressive was a lady who came to us she’d failed literally 12 prior therapy attempts 12 prior regimens she had a big tumor behind her left eye was pushing her eyeball forward she had tumors on the outside lining of her brain and in one
In her adrenal gland and this the tumor behind her eye completely resolved with our therapy went back into the eye socket uh there was improvements elsewhere marked um improvement in the quality of life and in the lifespan of this patient we believe uh and at the same time we think we’re having a positive effect on overall survival in the patients that we’re
Treating and that’s a really key parameter for the fda so that’s one thing is having the clinical efficacy another thing is having an experienced management team that knows how to get drugs approved and between myself and our chief medical officer dr del priory we’ve got 19 different drug approvals under our belt and the third thing would be a really good
Pipeline so you have multiple shots on goal and we have multiple uh new immunotherapy cell lines that are going to be coming into the clinic over the course of the next uh six to nine months so we’re very very excited we’re in a really good position and i think that um there’s a tremendous amount of value to be gained from brio cell stock wow congratulations
On your continued success it’s really great work you guys are doing and dr williams what would you say are the top three upcoming milestones for briocell so i think that there’s our ongoing clinical study is going to be generating additional patient data and that’s going to be coming out periodically over the course of the year um if we get some additional
Uh really uh fantastic responders that’ll become material information so we’ll have to put that out there so that’s one thing to look forward to another is our exciting off-the-shelf personalized approach to cancer which will be coming into the clinic we think around the middle of the summer and that’s a platform technology that’s going to give us multiple
Shots on goal it allows us to personalize and tailor our therapy to each individual patient and yet it’s off the shelf it doesn’t have a lot of the drawbacks that other personalized immunotherapies have like car t therapy where you have to manufacture each dose for each patient and i think the third thing is when we get enough patient data with our ongoing
Study to go down to the fda and negotiate that pivotal registration study design because that is when the big pharma companies really sit up and take interest and we start to talk about licensing deals and that’s something that we’re thinking of getting to around the fourth quarter of this year so there’s just a lot of big things coming up for bsl this year
Wow you guys are really really busy in your opinion is bria cell well funded for the time being or will you be looking to raise some funds in the near future so we’re in a very very fortunate position right now we raised funds when we uplifted to nasdaq in february of 2021 we raised funds again in june of 2021 and so now we have about a two-year runway that
Will get us through all the key milestones that we need to achieve the ongoing clinical study uh getting uh the uh pivotal study design with the fda approved and actually starting that study and then getting our off-the-shelf personalized immunotherapy cell lines into the clinic these things are all funded so it’s not just something that we’re thinking about
And that we’ll have to raise money to do but they’re already funded and if things go well we may actually never need to raise funds again because uh if we are able to execute a big deal with a big pharma company that may provide the funding that we need to execute our pipeline and to uh get into the things that we’re interested in so uh we’re in a very good
Position right now bill is there anything else you would want investors to know about bria cell therapeutics corp today so i think that uh just to give a little historical perspective we had a very tough time through the pandemic um we emerged from that uh in february of 21 and had to rebuild the company from scratch and the great news is that that rebuild
Is done now and we are clicking on all cylinders we’re moving forward and this year is going to be a transformational year for brieselle by this time next year we may have three four five or even six ongoing clinical studies we may have uh um our off-the-shelf personalized cell lines will all be in the clinic uh we we hope uh and uh we should have a pivotal
Study registration study design agreed with the fda and then we should either be in deep discussions with or will have already signed a deal with a big pharma company so this is what we’re striving to achieve this year and we think it’s going to be a transformational year for briocell well congratulations on all your success thus far what is the best way for
Investors to get in touch with the company if they have any questions about breast cell therapeutics corp so just go to our website www.briacell.org www.bsl.com and there’s ways there that you can uh you know get in touch with us uh by email or by phone or or whatever thank you so much for your time today dr bill williams the ceo of bria cell therapeutics
Corp thank you for joining us today bill it’s been an honor thank you so much for having us always a pleasure i must remind everyone that rich tv live is strictly for information education and entertainment purposes please do your due diligence do your research before you invest in anything we talk about or discuss here on rich tv live in saying that we do
Believe this is a company you need to put on your radar and put on your watch list right now take a put the attention on bctx in america on the nasdaq put it on your radar put on your watch list in canada symbol is bct put it on your radar put on your watch list if you’re not winning you’re probably not watching we bring you the winners and we bring them to
You first if you like the video please smash the like button comment down below share the video everywhere and subscribe and thank you for watching everybody this is your host rich from rich tv live with the ceo of bria cell therapeutics corp dr bill williams saying have a nice day everybody we’ll see you soon you
Transcribed from video
BriaCell Therapeutics Corp. (Nasdaq: BCTX) (TSX: BCT) CEO William Williams, MD – RICH TV LIVE By RICH TV LIVE
